VLON - Vallon surges after announcing strategic review process
The shares of nano-cap stock Vallon Pharmaceuticals (NASDAQ:VLON) are trading sharply higher on Friday after the Pennsylvania-based biopharma company said it engaged Ladenburg Thalmann & Co. to advise on strategic alternatives for the firm. The strategic review will include the evaluation of a potential for a merger, business combination, investment into the company or purchase, licensing, or other acquisition of assets, Vallon (VLON) said in a statement. The process may not lead to any transaction, the company cautioned, adding it would disclose additional details after entering into a specific transaction. Meantime, the company is streamlining operations with a view to preserve capital and liquidity. In addition, Vallon (VLON) said it was “continuing to assess the best path forward for” lead asset, ADAIR and ADMIR. The two experimental therapies are designed to target attention deficit hyperactivity disorder (ADHD).
For further details see:
Vallon surges after announcing strategic review process